Geron Corp (GERN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in two clinical trials: IMbark and IMerge in partnership with Janssen Biotech, Inc. IMbark is a Phase II, randomized, single-blind and multi-center study for patients with high risk myelofibrosis (MF) whose disease is relapsed after or refractory to JAK inhibitor treatment; and IMerge is a Phase 2/3, multi-center study of imetelstat in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS). Geron also has collaboration and royalty agreements with companies in oncology, diagnostics, biologics and research tools production domains. Geron is headquartered in Menlo Park, California, the US.

Geron Corp (GERN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

it derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 4
List of Figures 4
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Geron Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Geron Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Geron Corp, Medical Devices Deals, 2012 to YTD 2018 9
Geron Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Geron Corp, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 11
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 13
GE Healthcare Expands Licensing Agreement With Geron For Stem Cell Assays 15
Equity Offering 16
Geron Plans to Raise up to USD250 Million in Public Offering of Securities 16
Geron to Raise up to USD100 Million in Public Offering of Shares 17
Geron Plans to Raise up to USD50 Million in Public Offering of Shares 18
Geron Completes Public Offering Of Shares For US$103.5 Million 19
Geron Announces Public Offering Of Shares For Up To US$50 Million 21
Asset Transactions 22
BioTime Completes Acquisition Of Stem Cell Assets From Geron 22
Geron Corp - Key Competitors 24
Geron Corp - Key Employees 25
Geron Corp - Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Jul 31, 2018: Geron Reports Second Quarter 2018 Financial Results and Recent Company Events 27
May 10, 2018: Geron Reports First Quarter 2018 Financial Results 29
Mar 16, 2018: Geron Reports Fourth Quarter and Annual 2017 Financial Results and Recent Events 30
Nov 01, 2017: Geron Reports Third Quarter 2017 Financial Results 32
Aug 09, 2017: Geron Reports Second Quarter 2017 Financial Results 33
May 09, 2017: Geron Reports First Quarter 2017 Financial Results and Recent Events 34
Mar 01, 2017: Geron Reports Fourth Quarter and Annual 2016 Financial Results 36
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List Of Tables


Geron Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Geron Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Geron Corp, Deals By Therapy Area, 2012 to YTD 2018 8
Geron Corp, Medical Devices Deals, 2012 to YTD 2018 9
Geron Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Geron Enters into Licensing Agreement with Janssen Pharmaceuticals for RNA Interference 11
Geron Enters into Licensing Agreement with Janssen Biotech for Imetelstat 13
GE Healthcare Expands Licensing Agreement With Geron For Stem Cell Assays 15
Geron Plans to Raise up to USD250 Million in Public Offering of Securities 16
Geron to Raise up to USD100 Million in Public Offering of Shares 17
Geron Plans to Raise up to USD50 Million in Public Offering of Shares 18
Geron Completes Public Offering Of Shares For US$103.5 Million 19
Geron Announces Public Offering Of Shares For Up To US$50 Million 21
BioTime Completes Acquisition Of Stem Cell Assets From Geron 22
Geron Corp, Key Competitors 24
Geron Corp, Key Employees 25

List Of Figures


Geron Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Geron Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Geron Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Geron Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Geron Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Geron Corp, Medical Devices Deals, 2012 to YTD 2018 9

Geron Corp (GERN) - Medical Equipment - Deals and Alliances Profile

Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in

USD 250 View Report

Geron Corp (GERN) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in

USD 250 View Report

Geron Corp (GERN) - Medical Equipment - Deals and Alliances Profile

Geron Corp (Geron) is a clinical stage biopharmaceutical company, which develops a telomerase inhibitor as a potential treatment for cancer. The company is evaluating its flagship product candidate Imetelstat in

USD 250 View Report

Geron Corporation Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Geron Corporation Company Profile is a detailed strategic and analytical report on Geron Corporation. The 2018 version of the report offers detailed insights into the companys strategies, developments, outlook and

USD 200 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available